Research-based content. This article is based on published research and publicly available pricing data. It is not medical advice. Do not start, stop, or change any medication without consulting a licensed healthcare professional. See sources below.
Icotrokinra (Icotyde) in India — Psoriasis Treatment Price & Biologic Alternatives
Approximate Price Comparison (per month supply)
India
$150 – $400
US
$5,000 – $8,000
UK
$2,000 – $4,000
Prices are approximate and vary by dosage, brand, and pharmacy. Based on publicly available data.
Indian Manufacturers
The FDA approved Icotyde (icotrokinra) on March 18, 2026 — adding a new biologic mechanism (IL-19 targeting) to the psoriasis treatment arsenal. In the US, biologic psoriasis drugs cost $60,000–$96,000 per year. In India, biosimilar alternatives run $1,800–$4,800 annually.
The Psoriasis Biologic Landscape in 2026
Moderate-to-severe psoriasis affects approximately 125 million people worldwide. Biologic therapies have transformed treatment outcomes, with many patients achieving 90-100% skin clearance. But access is entirely dictated by cost and geography.
Currently available biologic classes for psoriasis:
| Drug Class | Example Drugs | US Annual Cost | India Annual Cost |
|---|---|---|---|
| TNF inhibitors | Adalimumab, Etanercept | $60,000 – $80,000 | $1,800 – $3,600 |
| IL-17 inhibitors | Secukinumab, Ixekizumab | $65,000 – $85,000 | $2,400 – $4,800 |
| IL-23 inhibitors | Guselkumab, Risankizumab | $55,000 – $75,000 | $2,000 – $4,000 |
| IL-19 inhibitor (NEW) | Icotrokinra | $60,000 – $96,000 | $1,800 – $4,800 (projected) |
India’s advantage: biosimilars for TNF inhibitors and IL-17 inhibitors already exist. Icotrokinra biosimilars will follow the same trajectory.
India’s Biosimilar Psoriasis Drugs
Indian-manufactured biosimilar biologics for psoriasis:
| Biosimilar | Originator | Indian Manufacturer | India Cost/Month |
|---|---|---|---|
| Adalimumab biosimilar | Humira | Biocon, Zydus, Intas | $150 – $250 |
| Etanercept biosimilar | Enbrel | Intas, Cipla | $200 – $350 |
| Infliximab biosimilar | Remicade | Biocon, Hetero | $100 – $200 |
These biosimilars have achieved regulatory approval from CDSCO, WHO, and in many cases the US FDA and European EMA. They are the standard of care at major Indian dermatology centers.
Medical Tourism for Psoriasis: The Full Picture
Treatment package at a major Indian hospital:
| Component | India Cost | US Cost |
|---|---|---|
| Dermatologist consultation | $30 – $60 | $300 – $500 |
| Psoriasis severity assessment (PASI scoring) | Included | $200 – $400 |
| Biologic loading dose (2 injections) | $300 – $700 | $10,000 – $16,000 |
| Phototherapy course (20 sessions) | $100 – $300 | $4,000 – $10,000 |
| Blood work (CBC, LFT, TB screening) | $20 – $40 | $500 – $1,000 |
| Total initial treatment | $450 – $1,100 | $15,000 – $27,900 |
Long-term savings model:
A psoriasis patient switching from US-priced biologics to Indian biosimilars saves approximately $50,000–$80,000 per year. Even accounting for two annual trips to India for treatment and medication, the net savings exceed $40,000 annually.
Why IL-19 Is a New Target
Most psoriasis biologics target IL-17, IL-23, or TNF — inflammatory molecules in the downstream cascade. Icotrokinra targets IL-19, which operates upstream in the inflammatory pathway specific to skin:
- May work for patients who have failed IL-17 and IL-23 inhibitors
- Different mechanism means different side effect profile
- Potential for combination therapy with existing biologics
For patients who have cycled through multiple biologics without adequate response (a growing population), IL-19 targeting represents a genuinely new option.
Practical Considerations
Starting biologics in India:
- Pre-treatment screening: TB testing (QuantiFERON or chest X-ray), hepatitis B/C serology, CBC — all available same-day at major hospitals for $20–$40
- Loading dose timing: Most biologics require doses at week 0 and week 2-4 — plan a 2-4 week initial stay
- Cold chain medications: Biologics require 2-8°C storage. Hospital pharmacies maintain cold chain; for travel, use insulated carriers
- Response assessment: Expect PASI improvement visible within 4-8 weeks of starting therapy
- Maintenance planning: Arrange ongoing supply through Indian pharmacy export (where legal) or plan return visits every 3-6 months
Sources & References
- FDA Approval — Icotyde (icotrokinra), March 18, 2026, for plaque psoriasis
- American Academy of Dermatology — Psoriasis treatment guidelines, 2026
- Indian Journal of Dermatology — Biologic therapy access in India, 2025
- Biocon — Biosimilar dermatology portfolio, 2026
- WHO Global Psoriasis Report — Burden of disease and access gaps
Frequently Asked Questions
What is Icotrokinra (Icotyde) and how does it work?
Icotrokinra is a biologic that targets IL-19, a cytokine involved in skin inflammation and psoriatic plaque formation. FDA-approved March 18, 2026, it represents a new mechanism of action for plaque psoriasis. Unlike IL-17 or IL-23 inhibitors, IL-19 targeting addresses a different part of the inflammatory cascade.
How much do biologic psoriasis treatments cost in India vs the US?
In the US, biologic psoriasis drugs cost $5,000–$8,000 per month ($60,000–$96,000/year). In India, biosimilar biologics for psoriasis (adalimumab, etanercept, secukinumab alternatives) cost $150–$400/month ($1,800–$4,800/year). This 85-95% price difference makes long-term biologic therapy accessible to Indian and medical tourism patients.
Which psoriasis biologics are available in India?
India has biosimilar versions of adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), and secukinumab (Cosentyx), plus branded biologics like ixekizumab and guselkumab. Indian companies like Biocon, Intas, and Zydus manufacture these at their own WHO-GMP facilities. Icotrokinra generics/biosimilars are expected once Indian regulatory filings are completed.
Is India a good destination for psoriasis treatment?
Yes. India offers comprehensive psoriasis care including biologics at 85-90% lower cost, phototherapy at $5–$15/session, and combination approaches. Major dermatology centers like AIIMS Delhi, Manipal Hospital, and Apollo have extensive experience treating international patients with moderate-to-severe psoriasis.
How long does psoriasis biologic treatment take?
Most biologics require an initial loading phase (2-4 doses over 4-8 weeks) followed by maintenance dosing every 2-4 weeks indefinitely. Medical tourists can start their loading phase in India, establish response, and continue maintenance either through return visits or by sourcing Indian-manufactured biologics through international pharmacy channels.
Disclaimer: This content is for informational and educational purposes only, based on published research and publicly available data. It does not constitute medical advice, diagnosis, or treatment recommendations. Drug prices are approximate and vary by dosage, formulation, brand, and pharmacy. Always consult a qualified healthcare professional before making any decisions about medication. Fittour India is not a pharmacy, drug seller, or licensed medical provider.